26
|
Ibach B. Themenschwerpunkt: Die Therapie nicht-kognitiver Störungen bei Demenzkranken mit Neuroleptika. ACTA ACUST UNITED AC 2008. [DOI: 10.1024/1661-4747.56.1.33] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Zusammenfassung: Der vorliegende Artikel diskutiert den potenziellen Nutzen und die Risiken einer neuroleptischen Behandlung von neuropsychiatrischen Symptomen bei Patienten mit Demenz. Verhaltensauffälligkeiten und psychosenahe Phänomene sind während des gesamten Krankheitsverlaufs hoch prävalent und belasten sowohl die Patienten als auch deren Angehörige. Die individuelle Berücksichtigung von Komorbiditäten und einer in der Regel vorhandenen Komedikation sind ebenso wie eine Symptomanalyse bereits vor Beginn einer neuroleptischen Therapie unentbehrlich. Neuroleptika gehören zu den bestuntersuchten Psychopharmaka überhaupt, verfügen über unterschiedliche pharmakologische Profile und werden sehr oft bei älteren Menschen verordnet. Neuere Studienergebnisse machen deutlich, dass Neuroleptika zwar wirksam sind, deren Anwendung jedoch aufgrund ihrer Nebenwirkungsprofile auf Patienten mit schweren klinischen Symptomen beschränkt bleiben sollte.
Collapse
|
27
|
Schumacher A, Friedrich P, Diehl-Schmid J, Ibach B, Eisele T, Laws SM, Förstl H, Kurz A, Riemenschneider M. No association of chromatin-modifying protein 2B with sporadic frontotemporal dementia. Neurobiol Aging 2007; 28:1789-90. [PMID: 16979267 DOI: 10.1016/j.neurobiolaging.2006.07.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2006] [Revised: 07/11/2006] [Accepted: 07/21/2006] [Indexed: 10/24/2022]
Abstract
Mutations of the chromatin modifying protein 2B gene (CHMP2B) were identified, in a Danish pedigree, to cause familial frontotemporal dementia (FTD). To explore the possible genetic contribution of common CHMP2B variants in sporadic FTD, we analyzed 14 single nucleotide polymorphisms covering the entire genomic region of CHMP2B. After adjustment for multiple testing single marker and haplotype analysis revealed no significant association with sporadic FTD. Thus, we conclude that CHMP2B can be excluded as a susceptibility gene conferring risk to sporadic forms of FTD.
Collapse
|
28
|
Laws SM, Perneczky R, Drzezga A, Diehl-Schmid J, Ibach B, Bäuml J, Eisele T, Förstl H, Kurz A, Riemenschneider M. Association of the tau haplotype H2 with age at onset and functional alterations of glucose utilization in frontotemporal dementia. Am J Psychiatry 2007; 164:1577-84. [PMID: 17898350 DOI: 10.1176/appi.ajp.2007.06091456] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE The microtubule-associated protein tau gene (MAPT) contains two extended haplotypes, H1 and H2, which have been linked with sporadic tauopathies. However, there is little evidence as to how these haplotypes may influence the clinical features of the disease. The aim of this study was to investigate the MAPT haplotypes in relation to risk for, and functional alterations of glucose metabolism in, patients with frontotemporal dementia (FTD). METHOD The authors investigated MAPT haplotypes in 142 individuals with FTD and 292 comparison subjects. Additionally, in a subset of 41 individuals with FTD and 16 comparison subjects, the authors undertook functional [ (18)F]fluorodeoxyglucose positron emission tomography (PET) imaging. RESULTS MAPT haplotype distribution did not differ significantly between individuals with FTD and comparison subjects. However, the H2 haplotype was clinically associated with an earlier age at onset of FTD, which presented in a dose-dependent manner. Correspondingly, PET analysis revealed functional differences in glucose utilization patterns between MAPT haplotypes, with H2 carriers having a more pronounced hypometabolism in frontal brain areas than H1 carriers, which could not be accounted for by differences in duration of illness. CONCLUSIONS While the extended MAPT H1 and H2 haplotypes do not appear to confer risk for disease development, the H2 haplotype appears to modify age at onset and functionally shows a more severe decline of glucose utilization in frontal brain areas.
Collapse
|
29
|
Ibach B, Gerwe M, Hargarter L, Czekalla J. Evaluating decision criteria for the choice of pharmacological long-term therapy in risperidone treated patients with schizophrenia. PHARMACOPSYCHIATRY 2007. [DOI: 10.1055/s-2007-991759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
30
|
Ibach B, Hargarter L, Gerwe M, Czekalla J. Time to clincal stabilization of in-patients with schizophrenia after conversion to long-acting risperidone. PHARMACOPSYCHIATRY 2007. [DOI: 10.1055/s-2007-991760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
31
|
Czekalla J, Ibach B, Gerwe M, Klose N, Hargarter L, Schreiner A. Interim analysis of 2-years non-interventional trial (LARA) shows tendency towards higher treatment adherence with less compliant schizophrenia patients under long-acting injectable risperidone (LAIR) compared to an oral atypicals (OA) treatment cohort. PHARMACOPSYCHIATRY 2007. [DOI: 10.1055/s-2007-991745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Gerwe M, Ibach B, Czekalla J. A naturalistic study of the effectiveness of oral risperidone (RIS) for the treatment of acute mania (RIS-BIM-0001). PHARMACOPSYCHIATRY 2007. [DOI: 10.1055/s-2007-991687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
33
|
Döhnel K, Sommer M, Ibach B, Rothmayr C, Meinhardt J, Hajak G. Neural correlates of emotional working memory in patients with mild cognitive impairment. Neuropsychologia 2007; 46:37-48. [PMID: 17915264 DOI: 10.1016/j.neuropsychologia.2007.08.012] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2007] [Revised: 08/10/2007] [Accepted: 08/18/2007] [Indexed: 11/26/2022]
Abstract
Emotional stimuli can have beneficial effects on memory in healthy aged subjects and partly on patients with dementia. So far, no experimental study has explored the effects of memory for emotional stimuli in patients with mild cognitive impairment (MCI), a concept that describes a transitional state between normal aging and dementia. The present fMRI study explored working memory for emotional stimuli in 16 patients with amnestic MCI (aMCI) and 16 healthy aged participants. Subjects performed an n-back task (2-back) with neutral, positive, and negative emotional pictures. The analysis focused on target processing. Results showed that groups did not differ in working memory performance. In healthy aged participants emotional targets had no significant impact on working memory. In patients with aMCI a negativity bias was observed, indicating that negative targets were better remembered compared to neutral and positive targets. Regarding fMRI results, both groups showed an increase in functional activity in prefrontal and lateral parietal brain regions associated with target processing. As a key result, we observed significant group by emotion interaction effects in the precuneus. Healthy aged participants showed a signal decrease in the left precuneus for positive compared to neutral targets. The precuneus deactivation in healthy aged participants may indicate a disengagement of self-referential processes towards task-related processes. Patients with aMCI revealed a signal increase in the right precuneus for negative compared to neutral targets. This increase in precuneus activity, combined with a behavioural facilitation effect, may indicate a mechanism to compensate disease related processes in aMCI.
Collapse
|
34
|
Schumacher A, Friedrich P, Diehl J, Ibach B, Schoepfer-Wendels A, Mueller JC, Konta L, Laws SM, Kurz A, Foerstl H, Riemenschneider M. No association of common VCP variants with sporadic frontotemporal dementia. Neurobiol Aging 2007; 30:333-5. [PMID: 17618707 DOI: 10.1016/j.neurobiolaging.2007.05.023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2006] [Revised: 03/20/2007] [Accepted: 05/27/2007] [Indexed: 11/23/2022]
Abstract
Mutations in the gene for valosin containing protein (VCP) cause autosomal dominant inclusion body myopathy associated with Paget disease and frontotemporal dementia (IBMPFD). To investigate the role of this novel gene in sporadic forms of frontotemporal dementia (FTD), we genotyped 27 single nucleotide polymorphisms covering the entire VCP genomic region in 198 patients with sporadic FTD and 184 matched controls from Germany. No significant association could be demonstrated. There is no evidence, that common variants in VCP confer a strong risk to the development of sporadic FTD.
Collapse
|
35
|
Schumacher A, Friedrich P, Diehl-Schmid J, Ibach B, Perneczky R, Eisele T, Vukovich R, Foerstl H, Riemenschneider M. No association of TDP-43 with sporadic frontotemporal dementia. Neurobiol Aging 2007; 30:157-9. [PMID: 17614162 DOI: 10.1016/j.neurobiolaging.2007.05.022] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2007] [Revised: 05/15/2007] [Accepted: 05/27/2007] [Indexed: 11/26/2022]
Abstract
A hyperphosphorylated, ubiquitinated form of TDP-43, known as pathologic TDP-43, was shown to be a central component of ubiquitin-positive, tau-negative and alpha-synuclein-negative inclusions in frontotemporal lobar degeneration (FTLD-U) and amytrophic lateral sclerosis (ALS). To investigate the role of the TDP-43 gene in sporadic forms of frontotemporal dementia (FTD), we genotyped 10 single nucleotide polymorphisms covering the entire TDP-43 genomic region, including the MASP2 gene in 173 patients with sporadic FTD (including 7 patients that were diagnosed with FTD and ALS) and 184 matched controls from Germany. Although we could observe a weak trend towards a potential disease association in a few FTD/ALS patients, no significant association with sporadic FTD could be demonstrated. There is no evidence, that common variants in TDP-43 confer a strong risk to the development of sporadic FTD.
Collapse
|
36
|
Riepe MW, Adler G, Ibach B, Weinkauf B, Tracik F, Gunay I. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine. Dement Geriatr Cogn Disord 2007; 23:301-6. [PMID: 17356273 DOI: 10.1159/000100875] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2006] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE Cholinergic therapy is used in mild-to-moderate Alzheimer's disease (AD) and antiglutamatergic therapy in moderate-to-severe AD. Global scales, as commonly used in clinical trials, blur specifics of disease progression and drug effects. The objective was to assess combination therapy of rivastigmine plus memantine by specific neuropsychological tests in patients with mild-to-moderate AD. METHODS 12-week-short multicenter open-label pilot study. Ninety patients with mild-to-moderate AD already on stable medication with rivastigmine (3-6 mg b.i.d.) additionally received memantine for 12 weeks. Subscales of the Alzheimer's Disease Assessment Scale (ADAS-cog), the Mini-Mental State Examination (MMSE) and additional neuropsychological tests (e.g. span tasks, semantic fluency) were assessed. RESULTS The scores in the ADAS-cog memory subscale, the MMSE score, and digit span and semantic fluency significantly improved on combination therapy. CONCLUSION Memory improvement was correlated with ADAS-cog memory score at baseline and inversely with age at onset of treatment. The data suggest that improvement on combination therapy results from an improvement of attention/executive function with secondary memory improvement, which will need to be confirmed in a subsequent double-blind study on a larger number of patients.
Collapse
|
37
|
Laws SM, Friedrich P, Diehl-Schmid J, Müller J, Ibach B, Bäuml J, Eisele T, Förstl H, Kurz A, Riemenschneider M. Genetic analysis of MAPT haplotype diversity in frontotemporal dementia. Neurobiol Aging 2007; 29:1276-8. [PMID: 17386961 DOI: 10.1016/j.neurobiolaging.2007.02.019] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2006] [Revised: 01/16/2007] [Accepted: 02/10/2007] [Indexed: 11/18/2022]
Abstract
The H1 haplotype of the tau gene, MAPT, has been linked to the sporadic tauopathies corticobasal degeneration and progressive supranuclear palsy; however, there have been inconsistent findings regarding association with frontotemporal dementia (FTD). We investigated MAPT haplotype diversity, in 171 sporadic FTD and 186 healthy controls individuals, and report no single marker or haplotype association with increased risk or changes in age at onset. These findings do not support an association of MAPT with FTD but do not rule out its association with other tauopathies.
Collapse
|
38
|
Gerwe M, Ibach B, Czekalla J, Moeller H. Cognitive effects of a prolonged-release formulation of galantamine (PRC) in patients with alzheimer's disease (AD) - an open-label phase-IIIb-study. Eur Psychiatry 2007. [DOI: 10.1016/j.eurpsy.2007.01.1015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
39
|
Ibach B, Gerwe M, Schwalen S, Riepe M. Cognitive function in patients with alzheimer's dementia and concomitant cerebrovascular disease treated with galantamine - a one year open-label phase-IIIb-study. Eur Psychiatry 2007. [DOI: 10.1016/j.eurpsy.2007.01.1016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
40
|
Ibach B, Hargarter L, Gerwe M, Czekalla J. Time to clinical stabilization and discharge from hospital treatment of patients with schizophrenia after conversion to long-acting risperidone (RIS-CONSTA), ris-siv-401. Eur Psychiatry 2007. [DOI: 10.1016/j.eurpsy.2007.01.369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
41
|
Czekalla J, Ibach B, Hargarter L, Gerwe M. Long-term adherence and health outcomes study with risperdal consta and oral atypicals in the treatment of schizophrenia patients (interim-analysis RIS-SCH-4023). Eur Psychiatry 2007. [DOI: 10.1016/j.eurpsy.2007.01.347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
42
|
Luckhaus C, Spiegler C, Ibach B, Fischer P, Wichart I, Sterba N, Gatterer G, Rainer M, Jungwirth S, Huber K, Tragl KH, Grünblatt E, Riederer P, Sand PG. Estrogen receptor beta gene (ESRbeta) 3'-UTR variants in Alzheimer disease. Alzheimer Dis Assoc Disord 2007; 20:322-3. [PMID: 17132983 DOI: 10.1097/01.wad.0000213861.12484.33] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
43
|
Riepe MW, Ibach B, Gerwe M. Galantamin verbessert kognitive Funktionen bei Patienten mit gemischter Demenz (Alzheimer-Demenz mit begleitender zerebrovaskulärer Erkrankung) – Ergebnisse einer offenen Ein-Jahresstudie der Phase IIIb. AKTUELLE NEUROLOGIE 2007. [DOI: 10.1055/s-2007-987944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
44
|
Gerwe M, Ibach B, Czekalla J. Interim analysis of a non-interventional study of risperidone (RIS) treatment of psychotic and behavioural symptoms in elderly patients with dementia and vascular risk factors previously treated with other neuroleptics. AKTUELLE NEUROLOGIE 2007. [DOI: 10.1055/s-2007-987947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
45
|
Möller HJ, Gerwe M, Ibach B, Czekalla J. Cognitive effects of a prolonged-release formulation of galantamine (PRC) in patients with Alzheimer's disease – An open-label phase-IIIb-study. AKTUELLE NEUROLOGIE 2007. [DOI: 10.1055/s-2007-987946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
46
|
Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E, Koch H, Putzhammer A, Kluenemann H, Wieland W, Hajak G. Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging 2006; 27:1202-11. [PMID: 16085339 DOI: 10.1016/j.neurobiolaging.2005.06.005] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2004] [Revised: 06/15/2005] [Accepted: 06/16/2005] [Indexed: 11/26/2022]
Abstract
We prospectively evaluated the diagnostic accuracy of cerebrospinal fluid (CSF)-beta-amyloid1-42 (Abeta42), -total-tau (tau) and -phosphorylated-tau181 (p-tau181) as measured by sandwich ELISAs in the clinical routine of a community state hospital to discriminate between patients with Alzheimer's disease (AD), healthy controls (HC), non-AD-dementias, a group composed of various psychiatric disorders (non-AD-dementias, mental diseases) and an age-matched random sample (RS) (total N=219). By comparing patients with AD to HC as reference, tau revealed sensitivity (sens)/specificity (spec) of 88%/80%, p-tau(181) 88%/80%, tau/Abeta42-ratio 81%/85% and phospho-tau(181)/Abeta42-ratio 81%/78%. Discriminative power between HC and all dementias under investigation was estimated lower for tau (78%/77%) and p-tau(181) (73%/79%). Relative to patients with AD, ROC analysis for the RS revealed highest sens/spec for p-tau181 (79%/77%) and p-tau181/Abeta42 ratio (78%/75%). Differentiation between AD versus a group made of patients with various psychiatric disorders was optimised by using CSF-p-tau181 (80%/77%). Under clinical routine conditions current CSF-biomarkers show a substantial capacity to discriminate between AD and HC as reference and to mark off AD patients from RS and heterogeneous diagnostic groups composed of non-AD dementias and other psychiatric conditions. Despite a residual substantial overlap between the groups, we conclude that current CSF markers are well suited to support AD-related diagnostic procedures in every-day clinics.
Collapse
|
47
|
Riepe MW, Adler G, Ibach B, Weinkauf B, Gunay I, Tracik F. Adding memantine to rivastigmine therapy in patients with mild-to-moderate alzheimer's disease: results of a 12-week, open-label pilot study. PRIMARY CARE COMPANION TO THE JOURNAL OF CLINICAL PSYCHIATRY 2006; 8:258-63. [PMID: 17235381 PMCID: PMC1764534 DOI: 10.4088/pcc.v08n0501] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/28/2005] [Accepted: 01/26/2006] [Indexed: 10/20/2022]
Abstract
OBJECTIVE At present, inhibition of cholines-terase is the treatment of choice for subjects with mild-to-moderate Alzheimer's disease (AD). Memantine, a noncompetitive antagonist at N-methyl-d-aspartate receptors, is currently used to treat subjects with moderate-to-severe AD. The goal of this multicenter, open-label pilot study was to investigate whether combination therapy with memantine added to rivastigmine is safe and beneficial in subjects with mild-to-moderate AD. METHOD Patients with a DSM-IV diagnosis of dementia of the Alzheimer's type (N = 95), who were treated with rivastigmine (6-12 mg/day) for a maximum duration of 24 weeks prior to baseline, received memantine (5-20 mg/day) in combination with rivastigmine for 12 weeks. The primary efficacy variable was the change in the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) total score at the end of 12 weeks compared with baseline. The study was conducted between September 15, 2003, and May 27, 2004. RESULTS There was a statistically significant difference between baseline and week 12 for the ADAS-cog total score, showing a positive effect of combination therapy. Combination therapy did not evidence any unexpected safety concerns and was well-tolerated by most patients. CONCLUSION Memantine in combination with rivastigmine appears to be safe and beneficial in patients with mild-to-moderate AD. Our results need to be confirmed in a large, long-term, randomized, double-blind, placebo-controlled clinical trial.
Collapse
|
48
|
Putzhammer A, Perfahl M, Pfeiff L, Ibach B, Johann M, Zitzelsberger U, Hajak G. Performance of diadochokinetic movements in schizophrenic patients. Schizophr Res 2005; 79:271-80. [PMID: 15987669 DOI: 10.1016/j.schres.2005.05.020] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2004] [Revised: 05/17/2005] [Accepted: 05/25/2005] [Indexed: 11/21/2022]
Abstract
Motor deficits are common and disabling symptoms in schizophrenic patients, which have enormous impact on the long-term outcome of the disease by affecting work performance and daily functioning. They are attributed to the disorder itself, as well as to treatment with dopamine-blocking antipsychotics. This study assessed the kinematic parameters of motor performance of a diadochokinetic hand movement in 20 drug-naïve, 20 conventionally treated (haloperidol or fluphenazine), and 20 atypically treated (olanzapine) patients, as well as in 20 healthy controls using a three-dimensional ultrasonic movement analysis system. It also tested differences in motor enhancement as induced by an attentional strategy and in dexterity advantages of motor performance for the dominant hand between the four study groups. Amplitude and peak velocity of diadochokinetic hand movements were significantly reduced in all patient groups compared to the controls, while frequency of the repetitive movement remained unaffected. The reduction was most pronounced in the conventionally treated patients. In addition, movement automation was impaired, primarily under conventional antipsychotic treatment. The study also revealed weaker effects of an attentional enhancing strategy on the movement amplitude in atypically and conventionally treated patients compared to both controls and drug-naïve patients. Alterations of dexterity could not be detected either in the drug-naïve or in the treated patients. The results indicate that patients with schizophrenia suffer from a specific primary motor deficit in diadochokinesia with reduction of amplitude and peak velocity. This deficit is significantly worsened by conventional antipsychotic treatment. Antipsychotic treatment additionally reduces the enhancing effect of an attentional strategy on motor performance.
Collapse
|
49
|
Ibach B, Haen E, Marienhagen J, Hajak G. Clioquinol Treatment in Familiar Early Onset of Alzheimer’s Disease. PHARMACOPSYCHIATRY 2005; 38:178-9. [PMID: 16025421 DOI: 10.1055/s-2005-871241] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Recently the metal chelator clioquinol (CQ) has been suggested as a possible option for treatment of Alzheimer's disease (AD). We report two patients with early onset of AD [one with a mutant amyloid-precursor-protein (APP) gene] who received long-term treatment with CQ. In both cases focally augmented cerebral glucose metabolism and stabilization but no amelioration of the clinical impression were observed without signs of neurotoxicity. In one case CSF-tau and beta-Amyloid (42/40) concentrations changed during CQ treatment.
Collapse
|
50
|
Klinger T, Ibach B, Schoenknecht P, Kamleiter M, Silver G, Schroeder J, Mielke R. Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study. Curr Med Res Opin 2005; 21:723-32. [PMID: 15969871 DOI: 10.1185/030079905x43668] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE This open-label, prospective, observational, Post-Marketing Surveillance (PMS) study assessed the efficacy and safety of donepezil in patients who had been switched from therapies currently used in Germany to treat Alzheimer's disease (AD), such as memantine and nootropics, due to insufficient efficacy or poor tolerability. A treatment-naive population was included as a comparator. RESEARCH DESIGN AND METHODS Patients with AD were treated with donepezil and observed for a period of approximately 3 months. A cognitive assessment was made using the Mini-Mental State Examination (MMSE). Quality of life (QoL) was assessed by the investigators who answered the question 'How did therapy with donepezil influence the QoL of the patient and/or his family over the observation period?' and was graded using three ratings: improved/unchanged/worsened. Adverse events (AEs) were also monitored. RESULTS A total of 913 patients entered the study (mean +/- SD MMSE score 18.03 +/- 5.34). Efficacy assessments were analyzed for three groups: an overall group of patients who had received any form of prior AD drug therapy (N+ group; n = 709); a subgroup of patients from the N+ group who had received prior memantine therapy only (M+ group; n = 111) and patients who were drug treatment naive (N- group; n = 204). In the evaluable population donepezil improved MMSE scores by 2.21 +/- 3.47 points on average, with similar improvements observed in all three groups. QoL was judged to be improved in at least 70% of patients, again with similar results obtained for all three groups. Donepezil was well tolerated, with 85 of 913 (9.3%) patients reporting AEs. The most common AEs were those typically seen with cholinergic therapies (i.e., diarrhoea, vomiting and nausea). CONCLUSIONS In this observational PMS study, donepezil was shown to be efficacious and well tolerated in patients who were being insufficiently treated with memantine or nootropic therapy. The magnitude of response was similar to that observed in patients who were previously treatment naive, suggesting prior medication does not effect donepezil's efficacy.
Collapse
|